WallStSmart

Bullish (BLSH)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Zepp Health Corp generates 9% more annual revenue ($258.90M vs $237.24M). BLSH leads profitability with a 0.0% profit margin vs -15.5%. ZEPP earns a higher WallStSmart Score of 41/100 (D).

BLSH

Avoid

35

out of 100

Grade: F

Growth: 8.0Profit: 2.5Value: 5.0Quality: 8.5
Piotroski: 3/9Altman Z: 64.93

ZEPP

Hold

41

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BLSH.

ZEPPUndervalued (+48.8%)

Margin of Safety

+48.8%

Fair Value

$46.82

Current Price

$18.43

$28.39 discount

UndervaluedFair: $46.82Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BLSH4 strengths · Avg: 9.3/10
Revenue GrowthGrowth
97.9%10/10

Revenue surging 97.9% year-over-year

Altman Z-ScoreHealth
64.9310/10

Safe zone — low bankruptcy risk

Debt/EquityHealth
0.199/10

Conservative balance sheet, low leverage

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.4x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

BLSH4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-27.6%2/10

ROE of -27.6% — below average capital efficiency

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$247.54M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : BLSH

The strongest argument for BLSH centers on Revenue Growth, Altman Z-Score, Debt/Equity. Revenue growth of 97.9% demonstrates continued momentum.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : BLSH

The primary concerns for BLSH are EPS Growth, Profit Margin, Piotroski F-Score.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

BLSH is growing revenue faster at 97.9% — sustainability is the question.

Monitor SOFTWARE - INFRASTRUCTURE industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ZEPP scores higher overall (41/100 vs 35/100) and 43.0% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Bullish

TECHNOLOGY · SOFTWARE - INFRASTRUCTURE · USA

Bullish provides market infrastructure and information services in United States. The company is headquartered in George Town, Cayman Islands.

Visit Website →

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?